Christopher E Rudd is a Professor of Medicine at the University of Montreal and Director of Immunology-Oncology at the Maisonneuve-Rosemont Hospital Research Centre (CR-HMR) as well as Adjunct Professor at McGill University.

He previously held professorial positions at the Harvard Medical School, the Dana-Farber Cancer Institute (Boston) and Cambridge University (UK). He has received awards from the Wellcome Trust (UK), Cancer Research Institute (New York) and the Leukemia/Lymphoma Society (USA) and is an elected Fellow of the Royal College of Pathologists (2002), the Academy of Medical Sciences (2002) and the Royal Society of Canada (2021). Professor Rudd’s research focus is on uncovering T-cell receptors and signaling mechanisms in immunotherapy and the therapeutic feasibility of novel small molecules in anti-tumor immunity.